EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Interleukin‐2 Deprived State of Regulatory T cells and Their Recovery by Low‐Dose Interleukin‐2 in Patients With Inflammatory Myopathies

Justus Ohmes, Luisa R Monne, Sara Comdühr, Fynn Gerlach, Hanna Grasshoff iD, Alexander Dübbers, Antje Müller, Alexander Scheffold, Gabriela Riemekasten, Reza Akbarzadeh iD, Jens Y Humrich iD

Arthritis & Rheumatology · 2026

DOI: 10.1002/art.70151 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arthritis & Rheumatology, 2026. Verfasst von Justus Ohmes und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Clinical Immunology, University Medical Center Schleswig-Holstein / University of Lübeck, Lübeck, Germany. Hauptthemen laut MEDLINE: T-Lymphocytes, Regulatory, Interleukin-2, Dermatomyositis, Polymyositis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft (DFG).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Regeneration and expansion of Treg by low‐dose interleukin‐2 (IL‐2) therapy is considered a potential treatment strategy for a wide range of autoimmune diseases. To provide a pathophysiologically‐based rationale for low‐dose IL‐2 therapy, we investigated whether reversible defects in the Treg–IL‐2 axis emerge in inflammatory myopathies.

Methods

CD4+ T cell subsets from patients with polymyositis (PM) or dermatomyositis (DM) (n = 20) and healthy controls (HC) (n = 19) and peripheral blood mononuclear cells (PBMC) from eight patients that were stimulated in vitro for 24 hours with different concentrations of recombinant human IL‐2 were analyzed by multicolor flow cytometry. Messenger RNA (mRNA) expressions of IL2RA , IL2RB , IL2RB , ENTPD1 , IKZF2 , and CTLA4 were quantified by real‐time polymerase chain reaction in IL‐2 stimulated PBMC (n = 6). Two patients with refractory PM/DM were treated with low‐dose IL‐2 therapy for eight weeks and monitored for clinical responses and changes in Treg subsets.

Results

Frequencies of Treg expressing CD25 at high levels (CD25hi Treg) and of CXCR5+ Treg were reduced in patients with PM/DM compared with HC ( P = 0.0052; P = 0.0661), particularly in active myositis ( P = 0.0036; P = 0.0335). Stimulation with low doses of IL‐2 selectively enhanced expression of CD25 molecules by Treg, leading to an increase in the CD25hi Treg subset ( P < 0.05) and augmented mRNA expression of several immunoregulatory molecules ( P < 0.05). Low‐dose IL‐2 therapy induced decreases in muscle enzymes that were accompanied by a sustained expansion of CD25+ Treg.

Conclusion

Our data suggest that shortage of IL‐2 is pathophysiologically relevant in PM/DM. Recovery and expansion of Treg by low‐dose IL‐2 therapy could thus be a promising targeted treatment option. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

T-Lymphocytes, RegulatoryInterleukin-2DermatomyositisPolymyositisMyositisHumansFemaleMaleAdultMiddle AgedRNA, MessengerInterleukin-2 Receptor alpha SubunitCTLA-4 AntigenAgedLeukocytes, MononuclearCase-Control StudiesIkaros Transcription Factor

Substanzen

Interleukin-2RNA, MessengerInterleukin-2 Receptor alpha SubunitCTLA-4 AntigenIkaros Transcription Factor

Autor:innen und Institutionen

  • Department of Rheumatology and Clinical Immunology, University Medical Center Schleswig-Holstein / University of Lübeck, Lübeck, Germany.
  • Institute of Immunology, University Medical Center Schleswig-Holstein / Christian-Albrechts-University, Kiel, Germany.

ORCID-Profile: Hanna Grasshoff, Reza Akbarzadeh, Jens Y Humrich

Förderung

  • Deutsche Forschungsgemeinschaft (DFG)

Zitieren

APA

Ohmes, J., Monne, L. R., Comdühr, S., Gerlach, F., Grasshoff, H., Dübbers, A., Müller, A., Scheffold, A., Riemekasten, G., Akbarzadeh, R., & Humrich, J. Y. (2026). Interleukin‐2 Deprived State of Regulatory T cells and Their Recovery by Low‐Dose Interleukin‐2 in Patients With Inflammatory Myopathies. Arthritis & Rheumatology. https://doi.org/10.1002/art.70151

Vancouver

Ohmes J, Monne LR, Comdühr S, Gerlach F, Grasshoff H, Dübbers A, et al. Interleukin‐2 Deprived State of Regulatory T cells and Their Recovery by Low‐Dose Interleukin‐2 in Patients With Inflammatory Myopathies. Arthritis & Rheumatology. 2026. doi:10.1002/art.70151

BibTeX
@article{Ohmes2026,
  author = {Ohmes, Justus and Monne, Luisa R and Comdühr, Sara and Gerlach, Fynn and Grasshoff, Hanna and Dübbers, Alexander and Müller, Antje and Scheffold, Alexander and Riemekasten, Gabriela and Akbarzadeh, Reza and Humrich, Jens Y},
  title = {Interleukin‐2 Deprived State of Regulatory T cells and Their Recovery by Low‐Dose Interleukin‐2 in Patients With Inflammatory Myopathies},
  journal = {Arthritis & Rheumatology},
  year = {2026},
  doi = {10.1002/art.70151}
}
Kostenlos starten →